PRESCRIPTION DRUGS: Medicare Overpaid $110 Million For Part B Drugs

Why This Topic Matters

The article highlights Medicare payment integrity concerns that may affect drug reimbursement, claim review, documentation practices, and compliance monitoring. It also points to broader policy and coverage discussions that can influence how providers bill and document allergy-related services under Medicare.

Article Sections

1. Part B drug payment methodology and reimbursement findings

   Discusses an HHS OIG review of Medicare Part B drug reimbursement and concerns about how payment calculations were being estimated. It also summarizes CMS’s response to the findings.

2. Allergen immunotherapy billing and standards of care

   Covers an HHS OIG report on Medicare allergen immunotherapy claims, including documentation, medical-necessity, and standards-of-care issues. It also mentions CMS and carrier-level policy concerns raised in the report.